Did patients do any better when enfuvirtide was part of their optimized background?
The difficulty in that question is that people aren’t randomized. Some people used it, some people didn’t. Some people were experienced with it, some people weren’t. I think the basic principle is that you want to use at least two fully active agents. In some cases that would be enfuvirtide and maraviroc … or any other fully active agent that you can get your hands on. I know with the other CCR5 inhibitors there have been problems with lymphoma. Was that ever confirmed? Did you see anything similar in this study? The other two CCR5 inhibitors that made it into clinical development: One was aplaviroc, which was discontinued because of hepatotoxicity, and that was not seen in the maraviroc studies; [the other is] vicriviroc, [which] is still in ongoing phase 2 studies. There’s a question of malignancies associated with the compound; however, it’s really not conclusive, and the numbers have been too small. In this particular study, there didn’t seem to be an increased risk of malignanci
